Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Ard van Veelen"'
1
Akademický článek
Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
Autor: Anita J.W. M. Brouns, MD, Ard van Veelen, MSc, G. D. Marijn Veerman, MD, Christi Steendam, MD, Safiye Dursun, MD, Cor van der Leest, PhD, Sander Croes, PhD, Anne-Marie C. Dingemans, MD, PhD, Lizza E.L. Hendriks, PhD
Publikováno v: JTO Clinical and Research Reports, Vol 4, Iss 5, Pp 100513- (2023)
Introduction: Bone metastases are frequent in patients with EGFR-mutated (EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We investigated the development
Externí odkaz: https://doaj.org/article/95d916a897b6469bb454b001cdb7dbeb
Zobrazit plný text záznamu
2
Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer
Autor: Ard van Veelen, Judith Gulikers, Lizza E.L. Hendriks, Safiye Dursun, Juanita Ippel, Egbert F. Smit, Anne-Marie C. Dingemans, Robin van Geel, Sander Croes
Publikováno v: van Veelen, A, Gulikers, J, Hendriks, L E L, Dursun, S, Ippel, J, Smit, E F, Dingemans, A-M C, van Geel, R & Croes, S 2022, ' Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer : The OSIBOOST trial ', Lung Cancer, vol. 171, pp. 97-102 . https://doi.org/10.1016/j.lungcan.2022.07.012
Lung Cancer, 171, 97-102. Elsevier Ireland Ltd
Introduction: Exposure to osimertinib, a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for treatment of non-small cell lung cancer (NSCLC) and a sensitizing EGFR mutation, can be substantially below average.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e90c1d695c2e87afae94bff515d7d9b5
http://www.scopus.com/inward/record.url?scp=85135538552&partnerID=8YFLogxK
Zobrazit plný text záznamu
3
Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run
Autor: Roy Schoufs, Sander Croes, Leo M L Stolk, Ard van Veelen, Robin M. J. M. van Geel, Yvo de Beer, Lizza E.L. Hendriks
Publikováno v: Biomedical Chromatography, 35(12):e5224. John Wiley & Sons Inc.
A liquid chromatography-tandem mass spectrometry method was developed and validated to quantify alectinib, crizotinib, erlotinib and gefitinib. This assay can be combined with our method for osimertinib, allowing quantification of the most used ALK-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e925fd334e3f034ad97627b5e60c1a9
https://cris.maastrichtuniversity.nl/en/publications/7e6fc3c6-8b8e-44d3-90f2-417723b90448
Zobrazit plný text záznamu
4
Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results
Autor: Sander Croes, Yvo de Beer, Robin M. J. M. van Geel, Anne-Marie C. Dingemans, Ard van Veelen, Frank de Vries, Rob ter Heine, Leo M L Stolk
Publikováno v: Biomedical Chromatography, 34, 4, pp. e4771
Biomedical Chromatography, 34, e4771
Biomedical Chromatography, 34(4), 1. John Wiley and Sons Ltd
Biomedical Chromatography, 34(4):e4771. John Wiley & Sons Inc.
Contains fulltext : 218134.pdf (Publisher’s version ) (Closed access) A new method for quantification of osimertinib (OSIM) in human plasma using a high-performance liquid chromatography-tandem mass spectrometry method was developed and validated.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8ba3860be9ffcb8a98f56076d9d06c9
https://doi.org/10.1002/bmc.4771
Zobrazit plný text záznamu
7
VP08 Real-World Data Use In Health Technology Assessments: A Comparison Of Five Health Technology Assessment Agencies
Autor: Hans L. Hillege, Amr Makady, Olaf Klunger, Ard van Veelen, Anthonius de Boer, Wim G. Goettsch
Publikováno v: International Journal of Technology Assessment in Health Care. 33:149-150
INTRODUCTION:Reimbursement decisions are usually based on evidence from randomized controlled trials (RCT) with high internal validity but lower external validity. Real-World Data (RWD) may provide complimentary evidence for relative effectiveness as
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::18b800487b2323c9402aaedcd1112c12
https://doi.org/10.1017/s0266462317003051
Zobrazit plný text záznamu
8
OP93 Conditional Financing In Health Technology Assessment Practice: The Dutch Experience
Autor: Hans L. Hillege, Amr Makady, Anthonius de Boer, Olaf Klunger, Hugo Nijmeijer, Ard van Veelen, Wim G. Goettsch
Publikováno v: International Journal of Technology Assessment in Health Care. 33:42-43
INTRODUCTION:In 2007, the National Healthcare Institute (ZIN) initiated conditional financing (CF) of expensive hospital drugs as an example of conditional reimbursement schemes (CRS). CF is a 4-year procedure encompassing initial HTA assessment (T =
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::645323a9980c8db72b64114f39ab9260
https://doi.org/10.1017/s0266462317001660
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje